Morocco’s healthcare system faces a rising cancer burden. Colorectal, breast, lung, and other cancers continue to strain public hospitals and national budgets. Local manufacturing covers a large share of essential medicines, yet complex oncology products—cytotoxic injectables, targeted therapies, and biosimilars—often depend on imports or limited domestic capacity. Against this backdrop, Moroccan stakeholders are increasingly looking